Technology firm ANGLE (LON:AGL) updated investors today on the development of portfolio company Novocellus' embryo viability product - EmbryoSure.
ANGLE owns 82 per cent of Novocellus, which specialises in IVF embryo viability.
Novocellus is in partnership with Origio - a supplier of IVF culture medium - and Origio is responsible for carrying out the final trials for the product, the firm said in a statement.
The market has previously been told that the trial for the product is delayed and the timeframe for completion of the tests is uncertain
"ANGLE is meeting with Origio at the end of this month to review options for progressing the trials.
"ANGLE remains confident of the potential for EmbryoSure to make a major impact in the IVF market," it said today.
Origio then have the right to license the EmbryoSure IP in exchange for milestone payments and a 25 per cent royalty on future sales.
Founder of ANGLE and chief executive Andrew Newland said: "We continue to believe that EmbryoSure has the potential to make a major impact in the IVF market and it is important to us that we get the trials completed and the product in the market as quickly as possible."
ANGLE added that a further announcement will be made once the position becomes clearer.